EN PL
REVIEW PAPER
Gout: the current look at diagnostics and treatment
 
More details
Hide details
 
Online publication date: 2010-12-19
 
 
Reumatologia 2010;48(6):425-428
 
KEYWORDS
ABSTRACT
Treatment and management in asymptomatic hyperuricemia especially in patients with the metabolic syndrome is presented. Early treatment of hyperuricemia in the case of hypertension and high cardiovascular risk seems to be necessary.
 
REFERENCES (29)
1.
Zhang W, Doherty M, Bardin J, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clini­cal Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324 (także: Medycyna Praktyczna 2007/6; wydanie specjalne, 39-48).  .
 
2.
Freig DI, Nakagawa T, Karumanachii SA, et al. Nephron Number, Uric Acid and Renal Microvascular Disease in The Patogenesis of Essential Hypertension. Kidney Int 2004; 66: 281-287.  .
 
3.
Lee J, Sparrow D, Vokonas S, et al. Uric acid and Coronary Heart Disease Risk: evidence for a Role of Uric acid in the Obesity-Insulin resistance Syndrome. Am J Epidemiol 1995; 142: 3-8.  .
 
4.
Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 2003; 44: 527-536.  .
 
5.
Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 929-933.  .
 
6.
Herman JB, Keyman A. Hyperglycemia and uric acid. Isr J Med Sci 1969; 13: 507-511.  .
 
7.
Herman JB, Medalie JH, Groen JJ. diabetes prevalence and serum uric acid. Observations among 10000 men in survey of ishaemic heart disease in Israel. Diabetes 1967; 16: 858-868.  .
 
8.
Padova J, Patchefsky A, Onesti G. The effect of glucose loads on renal uric acid excretion in diabetic patients. Metabolism 1964; 13: 507-511.  .
 
9.
Fox H, John D, Dwosh I, et al. Hyperuricemia and Hypertriglyceridemia: Metabolic Basis for the Association. Metabolism 1985; 34: 8-16. .
 
10.
Gibson T, Graham R. Gout and hyperlipidaemia. Ann Rheum Dis 1974; 33: 298-303. .
 
11.
Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-463. .
 
12.
Sundström J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33. .
 
13.
Kostka-Jeziorny K, Tykarski A. Związek hyperurykemii z innymi czynnikami ryzyka sercowo-naczyniowego u pacjentów z pierwotnym, nieleczonym nadciśnieniem tętniczym w populacji badania RISK. Arterial Hypertension 2008; 12: 190-199. .
 
14.
Cannella AC, Mikuls TR. Understanding treatments for gout. Am J Manag Care 2005; 11: S451-S458. .
 
15.
Toma I, Kang J, Meer E, et al. Uric acid triggers rennin release via a macula densa-dependent pathway. Presented at: American Society of Nephrology Annual Meeting; November 2007; San Francisco, CA. F-PO240. .
 
16.
Kostka-Jeziorny K, Tykarski A. Losartan, allopurynol – czy są dowody, że hiperurykemia może stać się kolejnym celem terapii w prewencji ryzyka sercowo-naczyniowego u pacjentów z nadciśnieniem tętniczym? Arterial Hypertension 2009; 13: 219-238. .
 
17.
Gibson T, Kilbourn K, Horner I. Mechanism and treatment of hypertriglyceridemia in gout. Ann Rheum Dis 1979; 38: 31-43. .
 
18.
Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1995; 141: 637-644. .
 
19.
Kanbay M, Ozkara A, Selcky Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-1233. .
 
20.
Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of uricosuric effect of DuP-, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335. .
 
21.
Athyros VG, Mikhaiilidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome. A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-127. .
 
22.
Zimmermann-Górska I. Aktualne możliwości leczenia chorych na dnę moczanową. Reumatologia 2009; 47: 75-81. .
 
23.
Markel A. Allopurinol – induced DRESS Syndrome. IMAJ 2005; 7: 656-660. .
 
24.
George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516. .
 
25.
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461. .
 
26.
Shumacher HR Jr, Becker MA, Wortman RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548. .
 
27.
Sundy JS, Baraf HS, Becker MA, et al. Efficacy and safety of intravenous (IV) Pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2. Arthritis Rheum 2008; 58 (Suppl): S400-S401. .
 
28.
Gigiel E, Hrycaj P. Nowe leki w leczeniu dny moczanowej. Reumatologia 2009; 47: 344-347. .
 
29.
Terkeletaub R. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther 2009; 11: 236 (doi:10.1186/ar2738).
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top